wei Liu

Dr. wei Liu

South China University of Technology, Guangzhou, Guangdong, China
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2016 in Leukemia
Verified
Journal Article
Closed access
PDF file
WLwei Liu
wei Liu
MWM Wu
M Wu
ZHZ Huang
Z Huang
JLJ Lian
J Lian
JCJ Chen
J Chen
WZW Zhang
W Zhang

4 March 2013 in Leukemia
Verified
Journal Article
Closed access
PDF file
JSJ Sun
J Sun
WLwei Liu
wei Liu
LLL Li
L Li
JCJ Chen
J Chen
MWM Wu
M Wu
WLWangjun Liao
Wangjun Liao

1 January 2018 in Development
Verified
Journal Article
Open access
PDF file
ZZZili Zhang
Zili Zhang
WLwei Liu
wei Liu
LZLingfeng Zhao
Lingfeng Zhao
ZHZhibin Huang
Zhibin Huang
XCXiaohui Chen
Xiaohui Chen
YZYiyue Zhang
Yiyue Zhang
T lymphocytes are key cellular components of an acquired immune system and play essential roles in cell-mediated immunity. T cell development occurs in the thymus where 95% of immature thymocytes are eliminated via apoptosis. It is known that mutation of Zeb1, one of the retinoblastoma 1 (Rb1) target genes, results in a decrease in the number of immature T cells in mice. E2F1, an RB1-interacting protein, has been shown to regulate mature T cell development by interfering with thymocyte apoptosis. However, whether Rb1 regulates thymocyte development in vivo still needs to be further investigated. Here, we use a zebrafish model to investigate the role of Rb1 in T cell development. We show that Rb1-deficient fish exhibit a significant reduction in T cell number during early development that it is attributed to the accelerated apoptosis of immature T cells in a caspase-dependent manner. We further show that E2F1 overexpression could mimic the reduced T lymphocytes phenotype of Rb1 mutants, and E2F1 knockdown could rescue the phenotype in Rb1-deficient mutants. Collectively, our data indicate that the Rb1-E2F1-caspase axis is crucial for protecting immature T cells from apoptosis during early T lymphocyte maturation.

22 February 2024 in Haematologica
Verified
Journal Article
Open access
PDF file
HLHaiping Luo
Haiping Luo
QLQiqi Li
Qiqi Li
JHJiaxin Hong
Jiaxin Hong
ZHZhibin Huang
Zhibin Huang
WDWenhui Deng
Wenhui Deng
WLwei Liu
wei Liu
T(1;19)(q23;p13) is one of the most common translocation genes in childhood acute lymphoblastic leukemia (ALL) and is also present in acute myeloid leukemia (AML) and mixed-phenotype acute leukemia (MPAL). This translocation results in the formation of the oncogenic E2A-PBX1 fusion protein, which contains a trans-activating domain from E2A and a DNA-binding homologous domain from PBX1. Despite its clear oncogenic potential, the pathogenesis of E2A-PBX1 fusion protein is not fully understood (especially in leukemias other than ALL), and effective targeted clinical therapies have not been developed. To address this, we established a stable and heritable zebrafish line expressing human E2A-PBX1 (hE2APBX1) for high-throughput drug screening. Blood phenotype analysis showed that hE2APBX1 expression induced myeloid hyperplasia by increasing myeloid differentiation propensity of hematopoietic stem cells (HSPCs) and myeloid proliferation in larvae, and progressed to AML in adults. Mechanistic studies revealed that hE2A-PBX1 activated the TNF/IL-17/MAPK signaling pathway in blood cells and induced myeloid hyperplasia by upregulating the expression of the runx1. Interestingly, through high-throughput drug screening, three small molecules targeting the TNF/IL-17/MAPK signaling pathway were identified, including OUL35, KJ-Pyr-9, and CID44216842, which not only alleviated the hE2A-PBX1- induced myeloid hyperplasia in zebrafish but also inhibited the growth and oncogenicity of human pre-B ALL cells with E2A-PBX1. Overall, this study provides a novel hE2A-PBX1 transgenic zebrafish leukemia model and identifies potential targeted therapeutic drugs, which may offer new insights into the treatment of E2A-PBX1 leukemia.

1 September 2020 in Journal of Genetics and Genomics
Verified
Journal Article
Closed access
WLwei Liu
wei Liu
QDQianqian Di
Qianqian Di
KLKailun Li
Kailun Li
JLJing Li
Jing Li
NMNing Ma
Ning Ma
YZYiyue Zhang
Yiyue Zhang

1 January 2019 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
AZAo Zhang
Ao Zhang
MWMei Wu
Mei Wu
JTJunliang Tan
Junliang Tan
NYNing Yu
Ning Yu
MXMengchang Xu
Mengchang Xu
YZYiyue Zhang
Yiyue Zhang
Benzene exposure is associated with various hematological disorders, in particular leukemia. The reactive metabolite of benzene, 1,4-benzoquinone (BQ), generated in bone marrow, is suggested to be a key molecule in mediating benzene-induced hematotoxicity and carcinogenicity. However, its pathogenic role remains largely unknown due to a lack of suitable vertebrate whole-organism models. Here, we present an in vivo study to reveal the effect of BQ exposure on hematotoxicity in zebrafish. From embryonic stages to adulthood, BQ exposure suppressed erythroid and lymphoid hematopoiesis but led to abnormal accumulation of myeloid cells and precursors, which resembles benzene-induced cytopenia and myeloid dysplasia in humans. This myeloid expansion is caused by granulocyte, but not macrophage, lineage, emphasizing the significant role of lineage specificity in BQ-mediated hematopoietic toxicity. Analysis of the c-myb (also known as myb)-deficient mutant cmybhkz3 revealed that BQ induced neutrophilia in a c-myb-dependent manner, demonstrating that c-myb is a key intrinsic mediator of BQ hematotoxicity. Our study reveals that BQ causes lineage-specific hematotoxicity in zebrafish from embryonic stages to adulthood. Since c-myb is indispensable for BQ to induce neutrophilia, c-myb could serve as a potential drug target for reversing BQ hematotoxicity.